Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Cronos Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Cronos Group Inc trades at $2.76 (market cap $1.02B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | CRON | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $3.27 |
52-Week Low | $23.09 | $1.95 |
Market Cap | — | $1.02B |
Enterprise Value | — | $200.66M |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CRON trades at $2.75, down 1.08% today. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent Q1 2026 earnings met expectations with $0.01 EPS, and the company expanded its Spinach brand and international footprint.
Outlook is mixed; strong revenue growth and market share gains in Canada and Israel offer upside, but profitability challenges and intense cannabis competition pose risks. Analyst consensus is cautious with 60% hold ratings. Key catalysts include continued international expansion and execution on cost management.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →